Headquartered in South Jordan, UT Fiscal year ends December NASDAQ: MMSI merit.com
Merit Medical Systems, founded in 1987, develops, manufactures and distributes proprietary medical devices used in interventional, diagnostic and therapeutic procedures. Its main clinical areas are cardiology, radiology, oncology, critical care and endoscopy. Revenue is organized into two platforms:
- Foundational: Access, OEM, Procedural Solutions, Vascular Intervention and Other.
- Therapeutic: Cardiac Therapies, Endoscopy, OEM, Oncology, Renal Therapies and Vascular Intervention.
The company sells worldwide through a domestic and international sales force and clinical support team of about 900 people, and employs about 7,500 people in total. In Q3 2026 roughly 61% of revenue came from the U.S. market.
Merit has been reshaping its portfolio through acquisitions and divestitures:
- Biolife Delaware, acquired May 2025.
- C2 CryoBalloon assets from Pentax of America, acquired November 2025.
- View Point Medical, acquired April 2026.
- DualCap anti-microbial cap line, sold to Health Line in February 2026.
- Solo Pace, Inc., acquired October 2026. Solo Pace makes the SOLO PACE CONTROL and FUSION temporary pacing systems for TAVR and other transcatheter heart valve procedures, expanding Merit's structural heart presence.
The company is completing its three-year Continued Growth Initiative program through 2026 while developing a longer-term strategic plan. Updated
With the Fed rate decision dropping at 2:30 PM and Alphabet and Microsoft reporting before the bell, Wednesday's analyst calls on Enphase, Spotify, Whirlpool, and a newly public Rangers franchise land at…
Pre-Market Stock Futures: The futures are trading flat after a big follow-through rally on Wednesday, which fed off the big gains generated on Tuesday. The big news after the closing bell was…
Pre-Market Stock Futures: Futures are trading higher as we prepare to wrap up one of the worst trading weeks in some time. The song remains the same as the rotation out of…
Merit Medical Systems, founded in 1987, develops, manufactures and distributes proprietary medical devices used in interventional, diagnostic and therapeutic procedures. Its main clinical areas are cardiology, radiology, oncology, critical care and endoscopy.
24/7 Wall St.'s 12-month price target for MMSI is $120.23, rated Buy. The Wall Street consensus target is $107.00. MMSI price prediction →
